These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16136646)

  • 1. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.
    Di Bisceglie AM; Sterling RK; Chung RT; Everhart JE; Dienstag JL; Bonkovsky HL; Wright EC; Everson GT; Lindsay KL; Lok AS; Lee WM; Morgan TR; Ghany MG; Gretch DR;
    J Hepatol; 2005 Sep; 43(3):434-41. PubMed ID: 16136646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.
    El-Serag HB; Kanwal F; Davila JA; Kramer J; Richardson P
    Gastroenterology; 2014 May; 146(5):1249-55.e1. PubMed ID: 24462733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT.
    Kobeisy MA; Morsy KH; Galal M; Sayed SK; Ashmawy MM; Mohammad FM
    Arab J Gastroenterol; 2012 Jun; 13(2):49-53. PubMed ID: 22980591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of alpha-fetoprotein in chronic hepatitis C.
    Tai WC; Hu TH; Wang JH; Hung CH; Lu SN; Changchien CS; Lee CM
    J Formos Med Assoc; 2009 Mar; 108(3):210-8. PubMed ID: 19293036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum α-fetoprotein levels in patients with chronic hepatitis C virus genotype 4: not the end of the story.
    Abdel-Razik A; Mousa N; Abdel-Aziz M; Elhelaly R; Elzehery R; Zalata K; Elkashef W; Fouda O; Awad M; Hafez M; Eldars W
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):313-22. PubMed ID: 26618566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.
    Morgan TR; Osann K; Bottiglieri T; Pimstone N; Hoefs JC; Hu KQ; Hassanein T; Boyer TD; Kong L; Chen WP; Richmond E; Gonzalez R; Rodriguez LM; Meyskens FL
    Cancer Prev Res (Phila); 2015 Sep; 8(9):864-72. PubMed ID: 26130251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy.
    Ji F; Zhou R; Wang W; Bai D; He C; Cai Z; Shen Y; Wang S; Deng H; Li Z
    J Interferon Cytokine Res; 2017 Aug; 37(8):362-368. PubMed ID: 28731786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development].
    Kim KA; Lee JS; Jung ES; Kim JY; Bae WK; Kim NH; Moon YS
    Korean J Gastroenterol; 2006 Nov; 48(5):321-6. PubMed ID: 17132920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
    El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
    Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma.
    Manuc D; Preda CM; Sandra I; Baicus C; Cerban R; Constantinescu I; Olteanu AO; Ciora CA; Manuc T; Chiriac DE; Chifulescu AE; Diculescu M; Tieranu C; Negreanu L; Oprea-Calin G; Manuc M
    J Med Life; 2020; 13(1):68-74. PubMed ID: 32341704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
    Takayama K; Furusyo N; Ogawa E; Ikezaki H; Shimizu M; Murata M; Hayashi J
    World J Gastroenterol; 2015 Apr; 21(15):4696-706. PubMed ID: 25914481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
    Giannini EG; Sammito G; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Trevisani F;
    Cancer; 2014 Jul; 120(14):2150-7. PubMed ID: 24723129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients.
    Omran MM; Farid K; Emran TM; Attallah AA
    Arab J Gastroenterol; 2011 Jun; 12(2):74-9. PubMed ID: 21684477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
    Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
    Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis.
    Stein DF; Myaing M
    Dig Dis Sci; 2002 Dec; 47(12):2686-90. PubMed ID: 12498286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
    Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
    Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase.
    Kim YI; Kim HS; Park JW
    PLoS One; 2016; 11(6):e0157299. PubMed ID: 27304617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
    Fouad R; Elsharkawy A; Abdel Alem S; El Kassas M; Alboraie M; Sweedy A; Afify S; Abdellatif Z; Khairy M; Esmat G
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1129-1134. PubMed ID: 30896550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.